Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Chong-Xian Pan, Ph.D., M.D.

Other Positions

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. CA210189 (Pan, Chong-xian) Jul 1, 2022 - Jun 30, 2025
    Department of Defense PRCRP IMPACT
    Quadrifunctional Cancer-Specific Microtheranostic Platform for the Management of Bladder Cancer
    Role Description: The major goal of this project is to develop a microtheranostic platform that combine photodynamic diagnosis and therapy, microbiotherapy and local immunotherapy in the same platform for intravesical instillation into the bladder cavity
    Role: PI
  2. 21VAL001 (Pan, Chong-xian) Jul 1, 2021 - Jun 30, 2026
    Prostate Cancer Foundation
    Blavatnik Family Foundation Precision Oncology Center of Excellence (COE) at VABHS-Dana-Farber Cancer Institute
    Role Description: The goal of this project is to establish VABHS as a regional precision oncology center for prostate cancer and provide cares to veterans with prostate cancer
    Role: PI
  3. I01CX002247 (PAN, CHONG-XIAN) Oct 1, 2020 - Sep 30, 2024
    A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
    Role: Principal Investigator
  4. W81XWH-19-1-0204 (Lam, Kit S) Jul 1, 2019 - Jun 30, 2023
    DoD Peer Reviewed Medical Research Program Expansion 3
    Delivery of targeting nano-photo-imiquimod to enhance response rate of advanced bladder cancer to check point blockade antibody therapy
    Role Description: The major goal is to develop bladder cancer-specific nanoporphyrin that can specifically delivery immunostimulator imiquimod to the bladder cancer, and potentiate photodynamic therapy and immunotherapy.
    Role: Co-PI
  5. R01CA222148 (LIU, XUEFENG) Jun 1, 2019 - May 31, 2023
    Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)
    Role: Co-Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023 Jan 16; 12(1):10. PMID: 36647169; PMCID: PMC9843946.
  2. Zhu Z, Ma AH, Zhang H, Lin TY, Xue X, Farrukh H, Zhu S, Shi W, Yuan R, Cao Z, Chittepu VCSR, Prabhala R, Li Y, Lam KS, Pan CX. Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer. Clin Cancer Res. 2022 11 01; 28(21):4820-4831. PMID: 35921526; PMCID: PMC9633390.
    Citations:    Fields:    Translation:AnimalsCells
  3. Rehman H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, Balasubramanya SAH, Shelton AK, Skinner KR, Ma AH, Rao T, Agarwal S, Eich ML, Robinson AD, Naik G, Manne U, Netto GJ, Miller CR, Pan CX, Sonpavde G, Varambally S, Ferguson JE. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight. 2022 08 22; 7(16). PMID: 35852858; PMCID: PMC9462490.
    Citations:    Fields:    
  4. Abd El-Salam MA, Smith CEP, Pan CX. Insights on recent innovations in bladder cancer immunotherapy. Cancer Cytopathol. 2022 09; 130(9):667-683. PMID: 35653623.
    Citations: 1     Fields:    
  5. Ravi P, Ravi A, Riaz IB, Freeman D, Curran C, Mantia C, McGregor BA, Kilbridge KL, Pan CX, Pek M, Choudhury Y, Tan MH, Sonpavde GP. Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma. Oncologist. 2022 05 06; 27(5):e406-e409. PMID: 35294031; PMCID: PMC9074964.
    Citations:    Fields:    Translation:Humans
  6. Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022 Mar 31; 41(1):119. PMID: 35361234; PMCID: PMC8969382.
    Citations: 1     Fields:    Translation:HumansCells
  7. Bekele RT, Samant AS, Nassar AH, So J, Garcia EP, Curran CR, Hwang JH, Mayhew DL, Nag A, Thorner AR, Börcsök J, Sztupinszki Z, Pan CX, Bellmunt J, Kwiatkowski DJ, Sonpavde GP, Van Allen EM, Mouw KW. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. J Clin Invest. 2021 11 15; 131(22). PMID: 34554931; PMCID: PMC8592548.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  8. Zhu S, Ma AH, Zhu Z, Adib E, Rao T, Li N, Ni K, Chittepu VCSR, Prabhala R, Garisto Risco J, Kwiatkowski D, Mouw K, Sonpavde G, Cheng F, Pan CX. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer. 2021 11; 9(11). PMID: 34725212; PMCID: PMC8562536.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  9. Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021 09 27; 14(1):156. PMID: 34579759; PMCID: PMC8475356.
    Citations: 42     Fields:    Translation:HumansAnimals
  10. Zhu S, Zhu Z, Ma AH, Sonpavde GP, Cheng F, Pan CX. Preclinical Models for Bladder Cancer Research. Hematol Oncol Clin North Am. 2021 06; 35(3):613-632. PMID: 33958154; PMCID: PMC8174399.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  11. Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett. 2021 04 28; 504:49-57. PMID: 33549708; PMCID: PMC7943249.
    Citations: 3     Fields:    Translation:Humans
  12. Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020 09 14; 11(1):4591. PMID: 32929084; PMCID: PMC7490264.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  13. Huang Y, Xue X, Li X, Jia B, Pan CX, Li Y, Lin TY. Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer. Adv Ther (Weinh). 2020 Oct; 3(10). PMID: 33072858; PMCID: PMC7567330.
    Citations: 1     
  14. Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere White R, Guo J, Pan CX. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunol Immunother. 2020 Nov; 69(11):2305-2317. PMID: 32506263.
    Citations: 4     Fields:    Translation:HumansAnimals
  15. Amaral R, Zimmermann M, Ma AH, Zhang H, Swiech K, Pan CX. A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models. Cancers (Basel). 2020 May 21; 12(5). PMID: 32455634; PMCID: PMC7281103.
    Citations: 5     
  16. Mondal AM, Ma AH, Li G, Krawczyk E, Yuan R, Lu J, Schlegel R, Stamatakis L, Kowalczyk KJ, Philips GK, Pan CX, Liu X. Fidelity of a PDX-CR model for bladder cancer. Biochem Biophys Res Commun. 2019 09 10; 517(1):49-56. PMID: 31303270; PMCID: PMC6777560.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  17. Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 08; 20:102004. PMID: 31055076; PMCID: PMC8237247.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  18. Xu X, Yang G, Xue X, Lu H, Wu H, Huang Y, Jing D, Xiao W, Tian J, Yao W, Pan CX, Lin TY, Li Y. A polymer-free, biomimicry drug self-delivery system fabricated via a synergistic combination of bottom-up and top-down approaches. J Mater Chem B. 2018 12 21; 6(47):7842-7853. PMID: 31380107; PMCID: PMC6676892.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  19. Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White RW, Pan CX, Li Y. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine. 2018 04; 14(3):789-799. PMID: 29317342; PMCID: PMC5898975.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  20. Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018 03; 32(3):1537-1549. PMID: 29146734; PMCID: PMC5892726.
    Citations: 128     Fields:    Translation:HumansAnimalsCells
  21. Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther. 2018 02; 17(2):474-483. PMID: 29284644.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  22. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 09 25; 7(1):12277. PMID: 28947782; PMCID: PMC5612935.
    Citations: 10     Fields:    Translation:HumansCells
  23. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6580-6591. PMID: 28808038; PMCID: PMC5668181.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  24. Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer. 2017 08 01; 141(3):604-613. PMID: 28437852; PMCID: PMC5497716.
    Citations: 6     Fields:    Translation:Humans
  25. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther. 2017 02; 16(2):376-387. PMID: 27903751; PMCID: PMC5335870.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  26. Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Diagnostic Microdosing Approach to Study Gemcitabine Resistance. Chem Res Toxicol. 2016 11 21; 29(11):1843-1848. PMID: 27657672; PMCID: PMC5385140.
    Citations: 5     Fields:    Translation:HumansCells
  27. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. PMID: 27640312; PMCID: PMC6522262.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  28. Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 2016 10; 104:339-51. PMID: 27479049; PMCID: PMC5412594.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  29. Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R. Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol. 2016 11; 196(5):1378-1382. PMID: 27208515; PMCID: PMC5319865.
    Citations: 13     Fields:    Translation:Humans
  30. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 05 01; 34(13):1500-9. PMID: 26926681.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  31. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One. 2016; 11(1):e0146256. PMID: 26799320.
    Citations: 12     Fields:    Translation:HumansCells
  32. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson PT, Pan CX. Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. Chem Res Toxicol. 2015 Dec 21; 28(12):2250-2. PMID: 26544157; PMCID: PMC4834887.
    Citations: 8     Fields:    Translation:HumansCells
  33. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481; PMCID: PMC4535951.
    Citations: 48     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  34. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. PMID: 25739672; PMCID: PMC4452427.
    Citations: 37     Fields:    Translation:HumansCTClinical Trials
  35. Tomlinson B, Lin TY, Dall'Era M, Pan CX. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond). 2015; 10(7):1189-201. PMID: 25929573; PMCID: PMC4562431.
    Citations: 10     Fields:    Translation:HumansAnimals
  36. Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One. 2014; 9(8):e105326. PMID: 25148033; PMCID: PMC4141800.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  37. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond). 2014; 9(12):1807-20. PMID: 24628688; PMCID: PMC4167557.
    Citations: 5     Fields:    Translation:AnimalsCells
  38. Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond). 2013 Aug; 8(8):1239-51. PMID: 23199207; PMCID: PMC3664656.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  39. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. PMID: 22745542; PMCID: PMC3383352.
    Citations: 17     Fields:    Translation:AnimalsCells
  40. Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine. 2012 Oct; 8(7):1116-24. PMID: 22197725; PMCID: PMC4577023.
    Citations: 11     Fields:    Translation:HumansCells
  41. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. PMID: 21128223; PMCID: PMC3145006.
    Citations: 21     Fields:    Translation:HumansCells
  42. Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011 Jan 27; 10(1):9. PMID: 21272294; PMCID: PMC3040722.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  43. Wang S, Zhang H, Cheng L, Evans C, Pan CX. Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res. 2010 Nov; 30(11):4573-8. PMID: 21115908; PMCID: PMC4562399.
    Citations: 6     Fields:    Translation:HumansCells
  44. Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. PMID: 21028869; PMCID: PMC2987236.
    Citations: 12     Fields:    Translation:HumansCells
  45. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. PMID: 20888272.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  46. Luo J, Zhang H, Xiao W, Kumaresan PR, Shi C, Pan CX, Aina OH, Lam KS. Rainbow beads: a color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries. J Comb Chem. 2008 Jul-Aug; 10(4):599-604. PMID: 18558750.
    Citations: 6     Fields:    Translation:HumansCells
  47. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, de Vere White RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15; 13(20):6204-16. PMID: 17947488.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  48. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007 Sep-Oct; 4(5):631-51. PMID: 17880166.
    Citations: 86     Fields:    Translation:HumansAnimals
  49. Wang X, Zhang S, MacLennan GT, Eble JN, Lopez-Beltran A, Yang XJ, Pan CX, Zhou H, Montironi R, Cheng L. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007 Feb 01; 13(3):953-7. PMID: 17289890.
    Citations: 22     Fields:    Translation:Humans
  50. Pan CX, Zhang H, Lara PN, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006 Dec; 6(12):1707-13. PMID: 17181484.
    Citations: 5     Fields:    Translation:Humans
  51. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer. 2004 Jul 01; 101(1):183-8. PMID: 15222005.
    Citations: 6     Fields:    Translation:HumansCells
  52. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM, Eble JN. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res. 2004 May 01; 10(9):3064-8. PMID: 15131044.
    Citations: 32     Fields:    Translation:Humans
  53. Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res. 2004 Feb 15; 10(4):1333-7. PMID: 14977833.
    Citations: 30     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Pan's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (245)
Co-Authors (15)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.